Latest Breaking News On - Clin cancer - Page 4 : comparemela.com

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

United statesDana farber cancer instituteAvelumab bavencioJamesa decaprioKangc retifanlimabAmerican society of clinical oncology annual meetingHarvard medical schoolMerkel cell carcinoma centerApproved agentsDual checkpointClinical oncology annualHarvard medicalCancer immunolClin cancerUnresectable or metastatic merkel cell carcinomaDana farber cancer institute

A Review of Anti-HER2 Targeted Agents in Non-Breast Solid Tumors

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

South koreaUniversity of washingtonUnited statesMegan alhadeffJavlem overexpressionThanh buiTiffany tamChemother pharmacolKanwal pratap singh raghavSalvatore sienaVan cutsemAtsuo takashimaDaiichi sankyoFred hutchinson cancer centerAmerican society for clinical pathologyAmerican society of clinical oncology

First Patient Dosed with LIXTE s LB-100 and GSK s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

First Patient Dosed with LIXTE s LB-100 and GSK s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesRoger pondelFlaurie bermanBiotechnology holdings incUniversity of texas md anderson cancer centerExchange commissionSecurities exchangePondelwilkinson incPatient dosedOvarian clear cell carcinomaAmir jazaeriGynecologic oncologySecurities actSecurities exchange actUnited states securitiesInvestor phone

First Patient Dosed with LIXTE s LB-100 and GSK s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

First Patient Dosed with LIXTE s LB-100 and GSK s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRoger pondelFlaurie bermanUniversity of texas md anderson cancer centerExchange commissionSecurities exchangeBiotechnology holdings incPondelwilkinson incAmir jazaeriGynecologic oncologySecurities actSecurities exchange actUnited states securitiesInvestor phoneExceptional survivalOvarian clear cell carcinomas treated

Frontline Camrelizumab/Rivoceranib Combination Shows Promise in Unresectable HCC

Amit Mahipal, MD, discusses data on camrelizumab plus rivoceranib in advanced hepatocellular carcinoma as well as the phase 3 CARES-310 trial, which is currently enrolling patients to receive the combination.

United statesComunidad autonoma de catalunaAmit mahipalDevelopmental therapeutics programUniversity hospitals seidman cancer centerCase comprehensive cancer centerBarcelona clinic liver cancerRobust data at primaryClin cancer